DYNAMICS OF THE LEVEL OF INFLAMMATION MARKERS IN PATIENTS WITH FRACTURES OF LONG BONES AGAINST THE BACKGROUND OF COVID-19

Authors:

Abstract:

The purpose of the study was to determine the response dynamics of inflammatory markers C-reactive protein and procalcitonin in patients with long bone fractures against the background of COVID-19. The main group included 157 cases of skeletal fractures against the background of COVID-19, and the control group included 132 cases of skeletal fractures in which there was no COVID-19 infection. The dynamics of the C-reactive protein level in patients with fractures against the background of COVID-19 indicated that this inflammatory marker is not informative at the initial stage, however, starting from the 3rd day, a significant increase in the C-reactive protein level was noted with a subsequent drop in the level in the postoperative period on the 10th day of treatment. The dynamics of the procalcitonin level was approximately the same during all observation periods and did not reflect the changes that occurred in patients with long bone fractures against the background of COVID-19, which does not allow the use of this inflammatory marker in the clinical diagnosis of the course of COVID-19 in patients with long bone fractures

Keywords:

trauma COVID-19 C-reactive protein procalcitonin

References:

1. Ashford RU, Nichols JS, Mangwani J. Annotation: The COVID-19 pandemic and clinical orthopaedic and trauma surgery. J Clin Orthop Trauma. 2020 Apr 2. doi: 10.1016/j.jcot.2020.04.002.
2. Heesom L, Rehnberg L, Nasim-Mohi M, Jackson AIR, Celinski M, Dushianthan A. et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist. 2020 Sep;22:782-784. doi: 10.1016/j.jgar.2020.07.017.
3. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020 Jan 16;70(3):538-542. doi: 10.1093/cid/ciz545.
4. Koozi H, Lengquist M, Frigyesi A. C-reactive protein as a prognostic factor in intensive care admissions for sepsis: A Swedish multicenter study. J Crit Care. 2020 Apr;56:73-79. doi: 10.1016/j.jcrc.2019.12.009.
5. Lippi G, Plebani M Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020 Jun;505:190-191. doi: 10.1016/j.cca.2020.03.004.
6. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 Jun;127:104370. doi: 10.1016/j.jcv.2020.104370. Epub 2020 Apr 14. PMID: 32344321; PMCID: PMC7194648;
7. Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. 2020 May 18;17(9):1281-1292. doi: 10.7150/ijms.46614.
8. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949.
9. Ryoo SM, Han KS, Ahn S, Shin TG, Hwang SY, Chung SP et al. The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: A multicenter prospective registry-based observational study. Sci Rep. 2019 Apr 29;9(1):6579. doi: 10.1038/s41598-019-42972-7.
10. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012.
11. Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019 Nov 12;19(1):968. doi: 10.1186/s12879-019-4618-7.

Publication:

«World of Medicine and Biology» Vol. 20 No. 88 (2024) , с. 156-161
УДК 617.5-001.1/.3-06:616.9

DOI:

https://doi.org/10.26724/2079-8334-2024-2-88-156-161